Navigation Links
United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
Date:2/14/2013

SILVER SPRING, Md., Feb. 14, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension.  The FDA classified the resubmission as a complete, class 1 response to FDA's October 23, 2012 complete response letter and the FDA set a user fee goal date of March 31, 2013.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique medicinal products.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the FDA's user fee goal date of March 31, 2013. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. United BioSource Corp. erweitert mit entscheidender Neubesetzung Potenzial in Europa
2. United BioSource Corp. expande sus capacidades europeas con contrataciones clave
3. United Kingdom Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
4. United States Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
5. Kevin Johnson Joins United Allergy Services Board Of Directors
6. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
7. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
8. Virtual Ports Receives Patent Approvals in the United States and Japan
9. United States Hospital Supplies Market Outlook to 2018 - Disposable Hospital Supplies, Mobility Aids and Transportation Equipment, Operating Room Equipment, Sterilization and Disinfectant Equipment and Others
10. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
11. Diet Doc Weight Loss Diets and Fast Weight Loss Plans To Seek Patent Protection for the Most Clinically Advanced Diet Offered in the United States.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Array BioPharma ... for the fourth quarter and full year of ... Ron Squarer, Chief Executive Officer of Array, noted, ... Phase 3, are on track for regulatory submissions ... in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... SenSage, Inc., a leading provider of ... that it has been selected as Cerner Corporation,s (Nasdaq: ... for its ability to demonstrate significant speed to value ... announced today an expanded alliance with Cerner to offer ...
... Codexis, Inc. (Nasdaq: CDXS ) ... with Teva Pharmaceutical Industries Ltd., the world,s largest ... technology transfer of custom biocatalysts for manufacture of ... have been transferred to pilot manufacturing and a ...
Cached Medicine Technology:SenSage Named Cerner Corporation's 'Accelerate Partner of the Year' 2SenSage Named Cerner Corporation's 'Accelerate Partner of the Year' 3SenSage Named Cerner Corporation's 'Accelerate Partner of the Year' 4Codexis Achieves Development Milestones With Teva 2
(Date:8/4/2015)... ... August 04, 2015 , ... Healthcare ... executives and technology professionals in healthcare and technology markets, today announced significant spikes ... of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related numbers solidify ...
(Date:8/3/2015)... ... ... of the economic recovery since the 2008 has been subject to much debate, the fact ... six years. Unemployment has dropped from a 2009 high of 10 percent to 5.9 percent, ... the U.S. stock market is at an all time high, and interest rates at near ...
(Date:8/3/2015)... ... August 04, 2015 , ... The American ... , The new internationally peer-reviewed Guidelines were prepared by members of the AAT ... imaging, in evaluating patients with dental-oral and systemic health-related complaints. , Thermography ...
(Date:8/3/2015)... ... , ... Sutter Health’s California Pacific Medical center announces the appointment of Hamila ... in her role effective immediately and will have responsibility for all aspects of operations ... Health for about 15 years, including the past 7 years as vice president of ...
(Date:8/3/2015)... Mich (PRWEB) , ... August 03, 2015 , ... Since ... country has declined, according to a new publication released today by the AAMC (Association ... black male college graduates over the past three decades, the number of black male ...
Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... to identify the agricultural areas with the greatest potential for ... ), which is at risk of extinction. The study shows ... Park of the Sierra de Cardea y Montoro, in Crdoba ... this species lives are the most appropriate sites ...
... , , , ... Healthcare, one of the nation,s first and leading providers of kidney ... the recipients of the 2009 Norman S. Coplon Extramural Grant Program. ... and medical centers in the United States and Canada who are ...
... , , , SAN DIEGO, ... company, today announced that the U.S. Court of Appeals for the ... over the validity of its patents that cover the methods for ... thiopurines to reach and maintain desired therapeutic levels (U.S. Patent Nos. ...
... , , Stable Medicare ... Quality Report , , WASHINGTON, Sept. ... Alliance for Quality Nursing Home Care (Alliance) characterized the health care ... as a step in the right direction, and said the process ...
... , WASHINGTON, Sept. 17 More than ... joint Open Letter to Congress declaring that the health care ... act now on meaningful reforms. They state that Congress has a ... , , The Open Letter identifies eight ...
... , , , ... advanced medical and aesthetic devices, introduces Smooth Cool HR/SR, a world-class ... the light based hair removal market. Smooth Cool HR/SR will make ... first thru third. "Smooth Cool HR/SR is designed for the practitioner ...
Cached Medicine News:Health News:Proposal to reintroduce Iberian lynx on abandoned agricultural land 2Health News:Satellite Healthcare Announces the Recipients of the 2009 Norman S. Coplon Extramural Grants 2Health News:Satellite Healthcare Announces the Recipients of the 2009 Norman S. Coplon Extramural Grants 3Health News:Appeals Court Rules in Favor of Prometheus, Upholds the Patentability of Its Claims for Methods of Thiopurine Metabolite Testing 2Health News:Baucus Approach to Financing Health Care Reform Step in Right Direction 2Health News:Leading American Healthcare Experts Press Congress to Act Quickly on Health Reform 2Health News:Leading American Healthcare Experts Press Congress to Act Quickly on Health Reform 3Health News:Leading American Healthcare Experts Press Congress to Act Quickly on Health Reform 4Health News:Eclipse Introduces Smooth Cool HR/SR with Unique Chilling Technology 2
CO 2 SMO-Capnograph/Pulse Oximeter...
A software program for simple, efficient pulse oximetry analysis, which enables easy viewing, analysis and report generation for pulse rate and SpO 2 ....
... the next generation in pulse oximetry monitoring ... current family of "digital pulse oximeters, MARSpO ... breakthroughs in signal processing. This provides improved ... superior performance during challenging clinical conditions such ...
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
Medicine Products: